Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a, Open-Label Study to Evaluate the Safety and Efficacy of AR882 Administered Alone or in Combination With Febuxostat or Allopurinol in Gout Patients

NCT04155918 is registered in ClinicalTrials.gov with Arthrosi Therapeutics as lead sponsor.

NCT NCT04155918
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04155918 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a, Open-Label Study to Evaluate the Safety and Efficacy of AR882 Administered Alone or in Combination With Febuxostat or Allopurinol in Gout Patients
Lead sponsor
Arthrosi Therapeutics
Phase
Phase 2
Overall status
Completed
Start date
February 3, 2020
Completion date
September 3, 2020
Enrollment
30 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gout patients